stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Free cash flow margin
Elanco Animal Health Incorporated's free cash flow margin over the twelve months to 30 June 2026 was 7.55%, up 1.5 percentage points from fiscal 2025 (6.02%). Over the past ten years it has ranged from −8.56% (fiscal 2020) to 11.8% (fiscal 2018); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 6.02% | (2.54) |
| FY2024 | 8.56% | 5.91 |
| FY2023 | 2.65% | (3.43) |
| FY2022 | 6.08% | 0.08 |
| FY2021 | 6.00% | 14.56 |
| FY2020 | −8.56% | (9.44) |
| FY2019 | 0.88% | (10.87) |
| FY2018 | 11.8% | 8.49 |
| FY2017 | 3.26% | 1.44 |
| FY2016 | 1.82% | (9.76) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 28.1% |
| LNTH Lantheus Holdings, Inc. compare | 26.2% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 20.9% |
| VTRS Viatris Inc. compare | 16.3% |
| ALKS Alkermes plc compare | 13.0% |
| ELAN Elanco Animal Health Incorporated | 7.55% |
| HIMS Hims & Hers Health, Inc. compare | 3.22% |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.88% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −1.89% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement